Scientist holding white laboratory mouse in hands

Lab mouse unrelated to study. (© filin174 - stock.adobe.com)

Effect Carries Over To Rodents With Alzheimer’s Disease Too, Giving Researchers Hope For Human Trials

In a Nutshell

  • Weekly nose drops carrying mRNA for the brain protein BDNF lifted memory scores in 18-month-old mice to match 3-month-old animals on three separate tests, with the two groups scoring too close to tell apart.
  • Nasal cells absorbed the lipid nanoparticles, produced BDNF and sent it to the brain, with synthetic protein confirmed in the olfactory bulb and hippocampus and no particle spread to the lungs or other organs.
  • In mice engineered to develop Alzheimer’s-type damage, the treatment lifted memory scores and left higher neuron counts in the hippocampus, while amyloid plaque buildup was unchanged.

Memory loss in old age has long looked like a one-way street. Researchers at the University of Sydney have found a detour, and it runs through the nose.

Elderly mice given weekly nose drops carrying genetic instructions for a brain protein called BDNF scored on memory tests like animals a sixth of their age. Mice bred to develop an aggressive form of Alzheimer’s disease, dosed twice a week from the age of two months, performed no differently from healthy animals of the same age. Findings were published in the journal Advanced Science.

Delivery is the trick here. Most drugs cannot reach brain tissue, blocked by a tight vessel lining called the blood-brain barrier. Rather than push a finished protein past it, the treatment hands nasal cells a recipe and lets them handle manufacturing on site.

Turning the Nose Into a Protein Factory

Brain-derived neurotrophic factor, better known as BDNF, works something like fertilizer for brain cells. It keeps neurons alive, strengthens the junctions between them and supports the birth of new ones in the hippocampus, the brain’s memory center. BDNF levels drop as humans age, and drop further in patients with Alzheimer’s disease. Restoring it has failed for an unglamorous reason: the protein cannot cross the blood-brain barrier. Past attempts have required surgery to infuse it directly into brain tissue. Sprayed up the nose in protein form, it degrades in the mucus within hours.

Study authors went after the problem sideways. Rather than deliver the protein, they delivered its blueprint. Messenger RNA coding for the mature form of BDNF was wrapped in lipid nanoparticles, the fatty-bubble delivery technology behind the COVID-19 vaccines. Genetic scaffolding for the mRNA itself came from the clinically validated BioNTech COVID-19 backbone, while the particles were built to the lab’s own lipid recipe. A single drop measuring 10 millionths of a liter went into the nostrils of lightly anesthetized mice. Cells lining the nasal passage absorbed the particles, read the instructions, produced BDNF and secreted it toward the brain.

As the authors put it in their paper, the setup “turns the nasal and olfactory epithelium into a local ‘drug factory'”.

Dr Maria Bergamasco in the Dr John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre.
First author Dr. Maria Bergamasco in the Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre. “The success of mRNA vaccines showed these systems can safely deliver genetic instructions to cells,” Dr Bergamasco said. (Credit Stefanie Zingsheim, University of Sydney)

Tracking dyes confirmed the particles stayed where they landed. Fluorescent signals appeared only in the respiratory and olfactory lining, with nothing detected in the lungs or other organs. A day after one dose, copies of the synthetic BDNF instructions ran 1,000 to 50,000 times higher than in control animals. Counts came from the nasal lining and the olfactory bulb, the brain’s smell-processing hub.

To prove the protein itself was making the trip rather than simply nudging the brain’s own supply, researchers tagged their synthetic BDNF with a molecular label. Tagged protein showed up strongly in the olfactory bulb and at low levels in the hippocampus.

Laboratory dishes supplied the first evidence that the manufactured protein actually worked. Human kidney cells given the mRNA secreted detectable BDNF within two hours, peaked at 24 hours and kept releasing it for up to four days. Fluid from those cells pushed adult mouse hippocampal stem cells to multiply faster and form more colonies when replated. Human nerve-like cells from a lab line, bathed in the same fluid, grew longer and bushier branches, matching the performance of commercially produced BDNF protein.

Memory Scores Climbed After Four Weekly BDNF Nasal Spray Doses

Eighteen-month-old mice, elderly by laboratory standards, received one microgram of the treatment once a week for four weeks, with a behavioral test 24 hours after each dose. Control animals got nose drops carrying mRNA for a harmless jellyfish protein. Three-month-old mice were tested as a youthful benchmark. Group sizes ran from six to 10 animals.

Results split cleanly. In an open-field test measuring anxiety-like behavior, treatment changed nothing. On memory, it changed a great deal. Treated animals outperformed age-matched controls on three tests: novel object recognition, a Y-maze test of working memory and a Y-maze test of spatial memory. Every gap cleared the standard statistical bar researchers use to rule out chance. Scores in all three landed close enough to the young control animals that statistical tests could not separate them. Groups this small, six to 10 animals, make that a weak form of evidence: failing to detect a gap is not the same as showing none exists. Memory gains were measurable after only two doses.

Professor Greg Neely and Dr Maria Bergamasco
Professor Greg Neely and Dr Maria Bergamasco (right) in the Dr John and Anne Chong Lab for Functional Genomics at the University of Sydney. “If we can proceed quickly to clinical trials in humans, this approach could represent a world-first non-invasive delivery system to treat Alzheimer’s that bypasses the blood-brain barrier,” Professor Neely said. (Credit: Stefanie Zingsheim, University of Sydney)

Brain tissue told a matching story. Treated aged mice carried 2.4 times as many hippocampal cells carrying a marker the authors use to count newly made neurons, and those cells grew more elaborate branches. Neither measure reached the levels seen in young mice, so the treatment did not rewind the aging brain wholesale even as behavior caught up.

Safety checks came back clean under the dosing used. Treated animals gained weight normally and showed no obvious side effects. After four doses, blood tests found no antibodies against PEG, a lipid component that can trigger immune reactions with repeated use, and no rise in three markers of inflammation. Nasal tissue showed no immune cell influx, and counts of microglia and astrocytes, the brain’s resident immune cells, held steady across the olfactory bulb, hippocampus and cortex.

Authors are direct about the ceiling on those checks, describing them as a first pass well short of a full safety workup.

A BDNF Nasal Spray Against Alzheimer’s Pathology

A second experiment used 5xFAD mice, a strain engineered to develop Alzheimer’s-type brain damage from two months of age and cognitive decline by four months. Treatment started at two months and ran twice weekly, totaling 24 doses through the end of behavioral testing. Treated animals beat their controls on novel object recognition and both Y-maze tests, and again scored indistinguishably from healthy wild-type animals of the same age.

Amyloid plaques, the protein clumps that define Alzheimer’s pathology, did not budge. What did change was the tissue around them. Treated 5xFAD mice carried more of those same marker-positive cells, with longer branches, plus higher counts of mature neurons in two parts of the hippocampus.

Authors read those counts as evidence the treatment blunted Alzheimer’s-driven cell loss. They frame the strategy as repair and support for ailing neurons, not an assault on the plaques themselves. They also float the idea of pairing it with anti-amyloid antibodies already approved for patients.

Mouse Noses Are Not Human Noses

Several gaps separate these nose drops from a pharmacy shelf, and the authors catalog them at length. Rodents have short nasal passages and a proportionally large olfactory region, which hands inhaled particles a short run to the olfactory bulb. In humans that region sits high in the nasal cavity, 4 to 7 centimeters from the nostrils, behind a longer and more divided airway. Scaling the mouse dose by body size works out to roughly 0.24 milligrams for a 60-kilogram adult.

Airflow, mucus clearance and individual anatomy differ enough, though, that rodent dosing cannot simply be converted. Delivery to deeper structures such as the entorhinal cortex, among the first regions Alzheimer’s damages, remains unproven.

Nor is intranasal delivery aimed at any particular brain region. BDNF acts differently depending on cell type, circuit and local receptor levels, so repeatedly raising it could in principle unbalance brain activity in ways short experiments would miss. Dementia treatment would mean dosing for years, which raises questions about nasal tissue tolerance that experiments on this timescale cannot settle.

Human testing of BDNF for Alzheimer’s is already underway, by a far more invasive route. One early-stage trial injects the gene directly into the brains of patients with early disease, guided by MRI. Against brain surgery, nose drops are a considerably easier sell. Proving they can clear the longer distance inside a human nose is now the work that matters.

“Before we can trial this therapy in patients, we need to perform a series of safety studies in animals,” said lead researcher Greg Neely, a professor at the University of Sydney’s Charles Perkins Centre, in a statement. “It is a very promising pathway but human noses are different from mouse noses so we will need to test our drugs in humans to before we know whether it will work.

“We believe our new drug, if it works in humans, can promote general cognitive health as people age, should help treat a variety of neurodegenerative diseases, and may even increase cognitive abilities in healthy young people,” he added.

Paper Notes

Limitations

Findings come entirely from mice and cultured cells, with behavioral group sizes of six to 10 animals per condition. Authors note that brain delivery was inferred from behavioral and tissue measurements rather than direct pharmacokinetic study, so human regional BDNF concentrations and deep-brain exposure cannot be predicted from this data. Anatomical differences weigh heavily: rodents have shorter nasal passages and a proportionally larger olfactory epithelium than humans, whose olfactory region sits 4 to 7 centimeters from the nostrils in the superior nasal cavity, meaning rodent work may overstate delivery efficiency to distant brain regions. Dose, frequency and device design optimized in mice cannot be extrapolated directly to people. Intranasal delivery is not region-specific, and because BDNF effects vary with cell type, circuit state and local TrkB receptor levels, sustained elevation could alter synaptic balance or excitability in unintended ways that this study was not designed to detect. Safety data gathered here cover body weight, serum IL-6, IL-33 and interferon gamma, and nasal and brain histology, which the authors frame as a preliminary check only; they call for longitudinal study of chronic dosing before any trial in Alzheimer’s patients. Aged-mouse testing used four doses over four weeks, and the authors acknowledge that more frequent or earlier dosing might produce larger effects. Treatment did not alter amyloid plaque load or astrocyte counts in the Alzheimer’s model, consistent with prior work showing BDNF does not modify amyloid pathology directly. Researchers’ construct encoded only the mature BDNF domain rather than the full-length sequence, so results may not generalize to full-length delivery.

Funding and Disclosures

L.L. was supported by the National Health and Medical Research Council (NHMRC) grant GNT2019264. G.G.N. was supported by the NHMRC (grants GNT2020532, GNT1185002, GNT1107514, GNT1158164, GNT1158165, GNT1046090, GNT1111940), the NSW Ministry of Health, and a donation from Dr. John and Anne Chong. S.B.C. has been supported by the NSW RNA Production & Research Network, an initiative of NSW Health (Australia). G.G.N. and M.B. are listed as inventors on a provisional patent application related to this work (2025906421). Remaining authors declared no competing interests. Data supporting the findings are available from the corresponding author upon reasonable request.

Publication Details

Maria Bergamasco, Hannah Scarborough, Anna Ponta, Teleri Clark, Scott B. Cohen, Lipin Loo, Kazuma Fujikake, Rebecca Carr, R.M. Damian Holsinger and G. Gregory Neely, “Bdnf mRNA-LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer’s Disease Mouse Models,” Advanced Science, 2026; 0:e78225. Bergamasco and Scarborough contributed equally as co-first authors. Author affiliations include the School of Life and Environmental Sciences and the Charles Perkins Centre, the Children’s Medical Research Institute, and the School of Medical Sciences, all at the University of Sydney, New South Wales, Australia. Corresponding author: G. Gregory Neely ([email protected]). Received 8 April 2026; revised 18 September 2026; accepted 29 September 2026. DOI: 10.1002/advs.78225. Published open access under a Creative Commons Attribution License.

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor